GC Green Cross Administers First COVID-19 Plasma Treatment to Domestic Patient

First Patient Dosed in Phase 2 Clinical Trial at Chung-Ang University Hospital

[Image source=Yonhap News]

[Asia Economy Reporter Seo So-jeong] GC Green Cross (CEO Heo Eun-cheol) announced on the 21st that it has completed the first patient administration in Phase 2 clinical trials of the COVID-19 plasma treatment ‘GC5131A’. The treatment was administered to the first patient one month after the Investigational New Drug (IND) approval on the 20th of last month.

The first patient administration took place on the 19th at Chung-Ang University Hospital under the leadership of Professor Jung Jin-won. GC Green Cross explained, "Procedures for additional patient administration are underway at a total of six medical institutions including Samsung Seoul Hospital, Seoul Asan Hospital, Chung-Ang University Hospital, Korea University Ansan Hospital, Yonsei Severance Hospital, and Chungnam National University Hospital."

GC Green Cross’s ‘GC5131A’ is classified as a new drug rather than a drug repositioning COVID-19 treatment in Korea. This clinical trial aims to evaluate the efficacy and safety of ‘GC5131A’ and to determine the appropriate dosage. It targets 60 patients with pneumonia confirmed by radiological diagnosis or high-risk patients who are elderly or have underlying diseases.

Kim Jin, Head of Medical Affairs at GC Green Cross, said, “We ask for continuous participation and interest from recovered patients for additional production of the formulation for treatment purposes,” and added, “Since this treatment is made possible by the power of the people, we will do our best to show meaningful results.”

Plasma collection is conducted at 46 ‘Blood Donation Centers’ nationwide. Recovered patients wishing to donate plasma can apply through the website (plasma.gccorp.com) or the call center (080-260-8232).

This content was produced with the assistance of AI translation services.